Dr. B R Shetty, Managing Director and CEO said that for Neopharma, a company operating in the branded generics segment, the ability to introduce new products in quick succession serves as an important competitive advantage. Significant among the new products to be introduced include Neoclav, a combination of amoxicillin and clavulanic acid. This combination therapy, used for the treatment of resistant infections, will lend significantly to Neopharma’s antibiotic mix.
Another key product introduced is Neosorbide that contains Isosorbide mononitrate, used for the management of angina. The drug comes in four different variations and includes the technology aided Sustained Release formulations. The introduction of this drug is a part of the company’s planned foray in cardiology. This assumes importance as chronic disorders are the leading cause of morbidity and mortality with cardiovascular disorders accounting to almost 24% of all deaths in UAE.
Enriching the product mix are the antacid range Neogastro & Neogastro Plus and a mucolytic Neosolvon used for certain respiratory disorders.
For Neopharma, 2006 will emerge as yet another crucial year as the company is gearing to introduce more new products, thanks to a robust R & D pipeline. The year will also witness the company spreading its wings across more overseas markets, a significant move towards globalisation.